step 1 trial semaglutide 2.4 mg weight loss nejm 2021 2.4-mg Injection as a Novel Approach for Chronic Management How long do you stay

A review on BPC-157 and gastric cytoprotection describes it as a stable gastric pentadecapeptide with anti-ulcer and tissue-protective effects and notes that it has been used in trials for ulcerative colitis

A 2023 preclinical study published in Nature Metabolism demonstrated that GLP-1 receptor activation suppressed reward-seeking behavior in animal models exposed to both food and alcohol cues

To put this in perspective, to justify their current valuation, they only have to grow their topline by ~7% for eight years while the overall obesity care market is expected to grow by ~26% CAGR

Yep, I crapped myself in public